Despite overwhelming evidence that extending coverage would save lives, donated kidneys, and money, policymakers remain, according to a new perspective piece in The New England Journal of Medicine, penny wise and pound foolish. [More]

Although it has seen some serious profit decreases in the last year, it looks like Amgen will keep a large anemia market share [More]

Nearly one in three dialysis clinics will receive a payment reduction under the new QIP. Is it the clinics, or the QIP, that need to improve? [More]



As CMS transforms how it reimburses for health care, it will need a leader to replace Berwick who can get the agency through the red tape. [More]

The third quarter reports for the renal industry are in, and while the profit picture is spotty, some companies are moving forward with investments in R&D and new products. [More]

DaVita and Amgen's stock have fallen on news of government inquiries and new ESA regulations, but some renal companies have seen rising prices. [More]

There were 3.5% more new ESRD patients in 2009 than in 2008, according to the 2011 United States Renal Data System report. [More]

According to the United States Renal Data System 2011 annual data report, hospital admissions for infections were 43% higher in 2009 than in 1993. [More]

Recent studies and surveys underscore need for better communication between doctors and kidney patients. [More]

Was Rep. Shelley Berkley's push to save a transplant center unethical? [More]